TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genedrive ( (GB:GDR) ) has provided an announcement.
Genedrive plc has announced the publication of the NHS implementation guide for CYP2C19 genotype testing, which supports prescribing decisions for stroke patients. The guide highlights the advantages of rapid testing, such as immediate results that facilitate timely treatment decisions, reducing the need for follow-up appointments. The Genedrive® CYP2C19 ID Kit is noted as the preferred rapid testing platform, and the company has been focusing on commercial efforts at the trust and Integrated Care Board level, as rapid testing funding must be sourced locally.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercializes rapid, low-cost, and easy-to-use point-of-care testing platforms for diagnosing genetic variants. These platforms provide clinicians with crucial genetic information to make informed decisions on medication choices and dosages, particularly in emergency healthcare settings. The company has launched the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both of which are recommended by NICE for use in the UK NHS.
Average Trading Volume: 56,858,051
Technical Sentiment Signal: Sell
Current Market Cap: £10.55M
See more data about GDR stock on TipRanks’ Stock Analysis page.